Surprising resignation: Teva's chief medical officer received another offer and leaves immediately
Dr. Eric Hughes, Teva's chief medical officer and head of global R&D, is leaving the company after receiving an external offer. Hughes held the position for the past four years and just last week presented the product pipeline at a conference in New York. The interim replacement is Dr. David Gardiner.
Dr. Eric Hughes, Teva's chief medical officer and head of global R&D, is leaving the company after receiving an external offer. Hughes held the position for the past four years and just last week presented Teva's product pipeline at an investor conference in New York. The company announced his departure is immediate, but he will remain for several months to assist with the transition. The interim replacement is Dr. David Gardiner, head of innovative medicines and clinical development, and Teva is beginning a search for a permanent replacement. CEO Richard Francis stated that Hughes made a significant contribution to the R&D organization and leaves Teva in a strong position. Teva emphasized that there is no change in strategy, and it continues to expect revenues of $6-7 billion from innovative medicines by 2030. Hughes managed 4,100 employees and was responsible for discovery, development, and safety in generics, biosimilars, and innovative medicines. Before Teva, he held senior positions at Vertex and Novartis.
Surprising resignation: Teva's chief medical officer received another offer and leaves immediately